Corbus Pharmaceuticals Holding Stock Current Ratio
| CRBP Stock | USD 17.47 0.74 4.42% |
Corbus Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Corbus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Corbus Stock. The fundamental analysis module provides a way to measure Corbus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corbus Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 0.74 | 0.70 |
Corbus | Current Ratio |
Corbus Pharmaceuticals Holding Company Current Ratio Analysis
Corbus Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Corbus Pharmaceuticals Current Ratio | 3.86 X |
Most of Corbus Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corbus Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Corbus Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Corbus Pharmaceuticals is extremely important. It helps to project a fair market value of Corbus Stock properly, considering its historical fundamentals such as Current Ratio. Since Corbus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corbus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corbus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Corbus Current Ratio Historical Pattern
Today, most investors in Corbus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Corbus Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Corbus Pharmaceuticals current ratio as a starting point in their analysis.
Corbus Pharmaceuticals Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Corbus Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Corbus Pharmaceuticals Holding has a Current Ratio of 3.86 times. This is 32.65% higher than that of the Biotechnology sector and 44.86% lower than that of the Health Care industry. The current ratio for all United States stocks is 78.7% lower than that of the firm.
Corbus Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corbus Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corbus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Corbus Pharmaceuticals by comparing valuation metrics of similar companies.Corbus Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Corbus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corbus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corbus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Corbus Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 57.02 M | ||||
| Shares Outstanding | 12.18 M | ||||
| Shares Owned By Insiders | 0.70 % | ||||
| Shares Owned By Institutions | 99.30 % | ||||
| Number Of Shares Shorted | 2.38 M | ||||
| Price To Earning | (8.87) X | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 163.32 X | ||||
| Gross Profit | (16.14 M) | ||||
| EBITDA | (44.44 M) | ||||
| Net Income | (44.6 M) | ||||
| Cash And Equivalents | 66.23 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 20.88 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 12.36 X | ||||
| Cash Flow From Operations | (36.1 M) | ||||
| Short Ratio | 5.39 X | ||||
| Earnings Per Share | (4.71) X | ||||
| Target Price | 59.5 | ||||
| Number Of Employees | 19 | ||||
| Beta | 2.57 | ||||
| Market Capitalization | 212.78 M | ||||
| Total Asset | 28.27 M | ||||
| Retained Earnings | (436.68 M) | ||||
| Working Capital | (8.35 M) | ||||
| Current Asset | 12.71 M | ||||
| Current Liabilities | 3.63 M | ||||
| Net Asset | 28.27 M |
About Corbus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corbus Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corbus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corbus Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Corbus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Corbus Stock
Moving against Corbus Stock
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.